biostudies-literatureHavens PLNICHD NIH HHSNCATS NIH HHSNCRR NIH HHSPHS HHS5619-28https://www.ebi.ac.uk/biostudies/studies/S-EPMC3811269biostudies-literatureUnknown57(11)Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV-infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross-sectional associations of TDF use with markers of renal function, vitamin D-calcium-parathyroid hormone balance, phosphate metabolism (tubular reabsorption of phosphate and fibroblast growth factor 23 [FGF23]), and bone turnover. Pharmacokinetic-pharmacodynamic associations with plasma tenofovir and intracellular tenofovir diphosphate concentrations were explored among those receiving TDF. The mean age was 20.9 (standard deviation [SD], 2.0) years; 63% weAntimicrobial agents and chemotherapyAssociation of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?PMC3811269M01 RR010710U01 HD 040474U01 A1068632UL1 TR002319M01 RR020359U01 HD 040533UL1 RR024134UL1 RR025014U01 HD040474M01 RR000188U01 HD040533UL1 RR024131U01 HD040497UL1 TR001082Kapogiannis BGHavens PLFlynn PMLiu NWoodhouse LRGordon CMVan Loan MDLujan-Zilbermann JPan CGStephensen CBBaker AHazra RBethel JWilson CMKiser JJRutledge BMulligan KAdolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study TeamfalseAssociation of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV-infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross-sectional associations of TDF use with markers of renal function, vitamin D-calcium-parathyroid hormone balance, phosphate metabolism (tubular reabsorption of phosphate and fibroblast growth factor 23 [FGF23]), and bone turnover. Pharmacokinetic-pharmacodynamic associations with plasma tenofovir and intracellular tenofovir diphosphate concentrations were explored among those receiving TDF. The mean age was 20.9 (standard deviation [SD], 2.0) years; 63% we2013-01-01T00:00:00Z2013 Nov2025-04-22T04:48:31.726Z2019-03-27T01:17:45ZS-EPMC38112692400209310.1128/AAC.01096-1310.1128/aac.01096-13